The U.S. Food and Drug Administration has approved SIMTRIYO (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients ages 6 and older who weigh at least 20 kilograms.
Developed by Otsuka Pharmaceutical, SIMTRIYO is an extended-release medication taken once daily. It introduces a new FDA-approved pharmacological approach to ADHD by inhibiting the reuptake of three neurotransmitters: norepinephrine, dopamine and serotonin. Although its mechanism differs from existing ADHD treatments, the FDA classifies SIMTRIYO as a central nervous system (CNS) stimulant.
